Cosopt Pf Generic Name & Formulations
Dorzolamide HCl 2%, timolol maleate 0.5%; oph soln; preservative-free.
Carbonic anhydrase inhibitor (sulfonamide) + noncardioselective beta-blocker.
Cosopt—10mL; Cosopt PF—60 (single-use 0.2mL containers)
Cosopt Pf Indications
Open-angle glaucoma or ocular hypertension where β-blocker alone is inadequate.
Cosopt Pf Dosage and Administration
Adults and Children
<2yrs: not recommended. 1 drop twice daily.
Cosopt Pf Contraindications
Asthma or history of asthma. Severe COPD. Sinus bradycardia. 2nd- or 3rd-degree AV block. Overt cardiac failure. Cardiogenic shock.
Cosopt Pf Boxed Warnings
Cosopt Pf Warnings/Precautions
Mild-to-moderate COPD or bronchospastic disease, or severe renal impairment: not recommended. Hepatic impairment. Surgery. May mask hypoglycemia or thyrotoxicosis. Myasthenia gravis. Discontinue if ocular effects occur. Soft contact lenses (remove, may reinsert 15 minutes after instillation). Discontinue at 1st sign of cardiac failure. Pregnancy (Cat.C). Nursing mothers: not recommended.
Cosopt Pf Pharmacokinetics
Cosopt Pf Interactions
Concomitant oral carbonic anhydrase inhibitors or other topical β-blockers: not recommended. May potentiate systemic β-blockers, reserpine, hypoglycemic agents, and mydriatic effects of topical epinephrine. May be potentiated by quinidine. May inhibit renal excretion of basic drugs and promote excretion of acidic drugs. May increase salicylate toxicity (acidosis). Possible conduction defects, left ventricular failure, or hypotension with calcium channel blockers, digoxin. May block epinephrine.
Cosopt Pf Adverse Reactions
Taste perversion; ocular burning, stinging, or itching; conjunctival hyperemia, blurred vision, superficial punctate keratitis; possible systemic effects.
Cosopt Pf Clinical Trials
Cosopt Pf Note
Cosopt Pf Patient Counseling